Table 3.
Adverse events (NCI-CTCAE v.4.0) 1.
| Toxicity | Grade, n (%) | |||
|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |
| Acute | ||||
| Mucositis Oral | 0 | 18 (60) | 12 (40) | 0 |
| Dermatitis | 18 (60) | 9 (30) | 3 (10) | 0 |
| Neutropenia | 12 (40) | 7 (23) | 4 (14) | 1 (3) |
| Anemia | 10 (33) | 12 (40) | 0 | 0 |
| Platelet count decreased | 1 (3) | 1 (3) | 1 (3) | 0 |
| Nausea | 7 (23) | 5 (17) | 1 (3) | － |
| Acute kidney injury | 1 (3) | 0 | 0 | 0 |
| Hepatobiliary disorders | 0 | 0 | 0 | 0 |
| Fever | 12 (40) | 2 (7) | 0 | 0 |
| Late | ||||
| Dry mouth | 14 (47) | 8 (27) | 0 | － |
| Dysgeusia | 7 (23) | 1 (3) | － | － |
| Osteonecrosis of jaw | 2 (7) | 2 (7) | 0 | 0 |
| Cataract | 0 | 2 (7) | 0 | 0 |
| Optic nerve disorder | 0 | 1 (3) | 0 | 0 |
| Middle ear inflammation | 1 (3) | 1 (3) | 0 | 0 |
1 NCI-CTCAE v.4.0, National Cancer Institute-Common Terminology Criteria for Adverse Events, version 4.0. n: number